Condition (MeSH)
Osteitis Deformans
ClinicalTrials.gov lists 21 trials for Osteitis Deformans or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Osteitis Deformans itself; the rest are tagged with a narrower condition beneath it.
When did Osteitis Deformans trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2016 | 2 |
| 2013 | 1 |
| 2009 | 1 |
| 2008 | 5 |
| 2007 | 3 |
| 2002 | 3 |
| 2001 | 2 |
| 1999 | 2 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 21 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteitis Deformans trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 5 |
| Phase 4 | 4 |
| Not applicable | 3 |
| Observational | 8 |
How many Osteitis Deformans trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 16 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Osteitis Deformans trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| Organon and Co | 1 |
| Sheba Medical Center | 1 |
| Takeda | 1 |
Which drugs are being tested for Osteitis Deformans? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| LAPATINIB | 2 |
| Pamidronate | 1 |
| TRASTUZUMAB | 1 |
| (nab)-paclitaxel | 1 |
| Ribociclib | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| acid Zoledronic | 5 |
| risedronate DR (Phase III clinical supply) | 3 |
| Alendronate 20 mg | 2 |
| Letrozol (Femara, Novartis) | 1 |
| Goserelin Depot | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Osteitis Deformans trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| NEUTROPENIA | 53 | 2 |
| HYPERTRANSAMINASAEMIA | 41 | 1 |
| DIARRHOEA | 27 | 2 |
| DYSPNOEA | 27 | 1 |
| PNEUMONIA | 26 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Osteitis Deformans? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Novel valosin-containing protein mutations associated with multisystem proteinopathy. | Neuromuscular disorders : NMD | 2018 | Yes |
| A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. | Neuromuscular disorders : NMD | 2018 | Yes |
| The Myoblast C2C12 Transfected with Mutant Valosin-Containing Protein Exhibits Delayed Stress Granule Resolution on Oxidative Stress. | The American journal of pathology | 2016 | Yes |
| 215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13-15 November 2015, Heemskerk, The Netherlands. | Neuromuscular disorders : NMD | 2016 | Yes |
| Psychological Impact of Predictive Genetic Testing in VCP Inclusion Body Myopathy, Paget Disease of Bone and Frontotemporal Dementia. | Journal of genetic counseling | 2015 | Yes |
Showing 5 of 40 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.